What is tesamorelin?
A synthetic GHRH analog peptide.

Tesamorelin is a synthetic peptide — a chain of 44 amino acids linked by peptide bonds — that replicates the full sequence of human growth hormone–releasing hormone (GHRH) with one deliberate chemical modification. Chemically, tesamorelin is classified as a GHRH analog rather than a GHRH mimetic: it is the same molecule as endogenous GHRH, not merely a compound that activates the same receptor. The only structural difference is the addition of a trans-3-hexenoic acid moiety — a short 6-carbon fatty acid with a double bond at position 3 — to the tyrosine residue at the N-terminal end of the peptide (Tyr1).

This hexenoyl modification serves a specific biochemical purpose. Native GHRH is degraded in plasma within minutes by the enzyme dipeptidyl peptidase-IV (DPP-IV), which cleaves the first two amino acids from the N-terminus and destroys the peptide's biological activity. The hexenoyl group on tesamorelin blocks DPP-IV access to the cleavage site, allowing the peptide to circulate long enough to reach pituitary GHRH receptors and trigger downstream GH release before it is cleared from the bloodstream.

Tesamorelin has a molecular weight of approximately 5,136 daltons (as the free base), placing it firmly in the peptide category rather than the small-molecule drug category. Its molecular formula is C₂₂₁H₃₆₆N₇₂O₆₇S. Because tesamorelin is a peptide, it cannot be taken orally — stomach acid and digestive enzymes would destroy it before it reached circulation. All tesamorelin administration is by subcutaneous injection, a route that allows the peptide to enter circulation intact.

Tesamorelin works by binding to growth hormone–releasing hormone receptors (GHRH-R) located on somatotroph cells in the anterior pituitary gland. Upon binding, tesamorelin activates the GHRH-R, which triggers a G-protein-coupled cascade that increases intracellular cyclic AMP (cAMP) and ultimately leads to the secretion of stored growth hormone (GH) into the bloodstream.

This is the same mechanism that endogenous GHRH uses. When the hypothalamus releases GHRH into the hypophyseal portal circulation, it travels the short distance to the anterior pituitary, binds GHRH-R, and triggers a GH pulse. Tesamorelin, injected subcutaneously and absorbed into systemic circulation, reaches the same receptor through a different anatomical route but activates it identically.

The GH that tesamorelin releases is the body's own stored GH, not exogenous GH. This distinction matters. Direct GH injection (somatropin) delivers a recombinant bolus of GH that is chemically identical to endogenous GH but produces a sustained, non-physiologic elevation. Tesamorelin, by contrast, triggers a natural pulse of endogenous GH that rises and falls within the normal physiologic range. The pituitary continues to respond to its own negative feedback — somatostatin, the body's GH-inhibiting hormone, still controls the pulse amplitude and duration. This preserves the pulsatile pattern of GH secretion that is characteristic of youthful, healthy endocrine function.

The released GH acts primarily through the liver, where it binds GH receptors and stimulates hepatic production of insulin-like growth factor 1 (IGF-1). IGF-1 is the downstream effector for most of GH's anabolic, lipolytic, and tissue-remodeling effects. Within days of starting tesamorelin peptide therapy, circulating IGF-1 levels rise measurably and enter the range associated with improved body composition, visceral fat reduction, and metabolic benefit.

The lipolytic effect on visceral adipose tissue — the clinical effect for which tesamorelin was FDA-approved — is mediated by GH itself, not IGF-1. GH directly stimulates hormone-sensitive lipase in visceral adipocytes, increasing the breakdown of triglycerides into free fatty acids. Visceral fat is more responsive to this GH-driven lipolysis than subcutaneous fat, which is why tesamorelin produces a selective VAT reduction effect rather than a general fat-loss effect. For a detailed breakdown of the downstream effects, see the tesamorelin benefits guide.

Tesamorelin has a plasma half-life of approximately 26–38 minutes following subcutaneous injection. Peak plasma concentration (Cmax) occurs roughly 15 minutes to 1 hour after injection, and the peptide is effectively cleared from circulation within 2–4 hours. This short pharmacokinetic window is important mechanistically — it means tesamorelin produces a single discrete GH pulse rather than sustained GH elevation, mirroring the physiologic pulsatile pattern of endogenous GHRH secretion.

The GH pulse itself is somewhat longer than the tesamorelin half-life because once pituitary GH is released, it circulates with its own GH pharmacokinetics (half-life ~20 minutes for GH, but with hepatic IGF-1 response that persists for hours). The cumulative effect is that a single morning 2 mg tesamorelin injection produces detectable IGF-1 elevation that persists throughout the day and returns to baseline overnight, ready for the next day's dose.

Tesamorelin is metabolized primarily by proteolytic enzymes and cleared from circulation with no significant hepatic cytochrome P450 metabolism. This means the drug has a clean drug-interaction profile — tesamorelin does not meaningfully affect the metabolism of other medications metabolized through the liver, and vice versa. The clinical trials did not identify drug-drug interactions of concern, though concurrent use of corticosteroids (which suppress GH response to GHRH) and concurrent use of other GH-modulating agents warrant clinical consideration.

DPP-IV resistance is the pharmacokinetic feature that distinguishes tesamorelin from native GHRH and from shorter GHRH fragments like sermorelin. Sermorelin, which consists of only the first 29 amino acids of GHRH, is still DPP-IV-sensitive and has a much shorter functional half-life (~10–15 minutes) than tesamorelin. This is why sermorelin requires larger or more frequent doses to produce equivalent GH release, and why tesamorelin has consistently demonstrated greater potency in head-to-head research comparisons. See the tesamorelin vs sermorelin comparison for the complete pharmacokinetic and clinical comparison.

Tesamorelin is FDA-approved for a single indication: the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Lipodystrophy is a body-composition disorder historically associated with older antiretroviral regimens in which patients accumulate visceral abdominal fat while losing subcutaneous fat in the face and extremities. Tesamorelin specifically addresses the visceral fat accumulation component of this condition and was approved in November 2010 on the basis of the Falutz Phase III trials, which showed approximately 15% VAT reduction over 26 weeks of treatment.

Beyond the on-label indication, tesamorelin peptide is used off-label for several research and clinical applications, all of which extend from the same underlying mechanism — restoration of pulsatile GH secretion and the resulting reduction in visceral adipose tissue:

Non-alcoholic fatty liver disease (NAFLD / MASLD). A 2014 JAMA study by Stanley et al. showed 32% liver fat reduction at 12 months of tesamorelin therapy in HIV patients with NAFLD. This has driven growing off-label interest in tesamorelin for metabolic-associated steatotic liver disease in non-HIV populations, where no FDA-approved pharmacologic therapy specifically targets liver fat.

Age-related growth hormone decline. Adult growth hormone secretion declines progressively from the early 20s onward, and low GH is associated with increased central adiposity, reduced lean mass, impaired recovery, and worse sleep quality. Tesamorelin offers a way to restore pulsatile GH signaling without the non-physiologic effects of direct GH injection.

Body composition and visceral fat reduction. Non-HIV adults with central adiposity — particularly those with metabolic syndrome or cardiovascular risk profiles — use tesamorelin off-label for VAT reduction. The 15–20% reduction seen in clinical trials is maintained in this population, though long-term outcome data specifically in non-HIV use is limited.

Research into GH pulsatility. Because tesamorelin produces physiologic rather than supraphysiologic GH pulses, it is used in research settings to study the effects of restored GH pulsatility on metabolic, cognitive, and body composition endpoints — research that would be confounded by the sustained GH elevation produced by direct somatropin injection.

Growth hormone pharmacology includes several related compound classes that are frequently confused. Understanding what tesamorelin is requires understanding what it is not.

Tesamorelin vs endogenous GHRH. Tesamorelin is structurally the full 44-amino-acid GHRH sequence with a hexenoyl protection group. Mechanistically, tesamorelin IS GHRH — it binds the same receptor and triggers the same downstream response. The only functional difference is half-life: tesamorelin survives in circulation ~3–5x longer than native GHRH because of DPP-IV resistance.

Tesamorelin vs sermorelin. Sermorelin is a truncated 29-amino-acid fragment of GHRH (specifically GHRH(1-29)), not the full sequence. It activates the same receptor but with lower potency and much shorter half-life because it lacks the DPP-IV protection that tesamorelin carries. Clinically, tesamorelin produces larger VAT reductions and stronger IGF-1 elevation at comparable doses. See tesamorelin vs sermorelin for the complete comparison.

Tesamorelin vs ipamorelin and CJC-1295. Ipamorelin is a growth hormone secretagogue (GHS) — a ghrelin receptor (GHSR) agonist — not a GHRH analog. It triggers GH release through a different receptor pathway, which is why tesamorelin and ipamorelin are complementary when stacked (the two mechanisms amplify each other rather than compete). CJC-1295 is another GHRH analog, similar to tesamorelin in mechanism, but with different pharmacokinetics depending on whether it is the short-acting "CJC-1295 without DAC" (minutes) or long-acting "CJC-1295 with DAC" (days to a week).

Tesamorelin vs HGH (somatropin). Tesamorelin is not growth hormone. HGH, also called somatropin, is recombinant human growth hormone itself — the downstream effector that GHRH triggers. Direct HGH injection bypasses the pituitary entirely and produces sustained, non-physiologic GH elevation. Tesamorelin preserves the physiologic feedback loop: it triggers the pituitary to release its own GH in natural pulses subject to somatostatin negative feedback.